Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study - Schwarz, T; Spaczynski, M; Kaufmann, A (BJOG, 2015)
et al.